drugset / Trial / NCT01016977

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

NCT01016977

Phase 4 Completed 40 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

A single-blind (investigator-blinded), randomized, parallel group, single center study to evaluate the tolerability and efficacy of combination therapy with Duac Gel / 0.1% Tazorac Cream and Acanya Gel / 0.1% Tazorac Cream for the treatment of facial acne vulgaris.

Timeline

Start
2009-10
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator CLNP-BPO2.5 Unknown 1.2 % Topical
Comparator CLNP-BPO2.5 Unknown 2.5 % Topical
Comparator CLNP-BPO5 Unknown 1 % Topical
Comparator CLNP-BPO5 Unknown 5 % Topical
Comparator Tazarotene Small molecule 0.1 % Topical

Indications